CD29 (Integrin beta 1) Monoclonal Antibody (eBioHMb1-1 (HMb1-1)), eBioscience™, Invitrogen™

Description

Description: The eBioHMb1-1 monoclonal antibody reacts with mouse and rat CD29 (integrin beta 1), a 110-120 kDa member of the beta integrin family expressed by leukocytes, endothelial, smooth muscle and epithelial cells. CD29 binds non-covalently with the alpha integrins CD49a-f to form the VLA-1 through VLA-6 complexes, as well as with CD51. These alpha-beta integrin heterodimers are capable of mediating a variety of cellular responses including adhesion, trafficking, proliferaton and differentiation. All integrins which include CD29 bind to extracellular matrix proteins including collagen, laminin, fibronectin and vitronectin, whereas some CD29-containing integrins can also interact with cellular receptors such as VCAM-1 and MadCAM-1. Applications Reported: This eBioHMb1-1 (HMb1-1) antibody has been reported for use in flow cytometric analysis, and immunoprecipitation. (Please use Functional Grade purified eBioHMb1-1 (HMb1-1), cat. 16-0291, in functional assays.). Applications Tested: This eBioHMb1-1 (HMb1-1) antibody has been tested by flow cytometric analysis of mouse spleen, thymus and bone marrow cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered. CD29 (beta1 integrin subunit, GPIIa) forms non-covalently linked heterodimers with at least 6 different alpha chains (alpha1-alpha6, CD49a-f) determining the binding properties of beta1 (VLA) integrins. These integrins mediate cell adhesion to collagen, fibronectin, laminin and other extracellular matrix (ECM) components. This interaction hinders cell death, whereas disruption of anchorage to ECM leads to apoptosis. Decreased expression of most beta1 integrins correlates with acquiring multidrug resistance of tumour cells during selection in presence of antitumour drug. In platelets, translocation of intracellular pool of beta1 integrins to the plasma membrane following thrombin stimulation. These integrins are also up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue, as well as in regulating tissue damage and disease symptoms related to inflammatory bowel disease. Through a beta1 integrin-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1beta.